CA3002915C - Plasminogen replacement therapy for plasminogen-deficiency - Google Patents

Plasminogen replacement therapy for plasminogen-deficiency Download PDF

Info

Publication number
CA3002915C
CA3002915C CA3002915A CA3002915A CA3002915C CA 3002915 C CA3002915 C CA 3002915C CA 3002915 A CA3002915 A CA 3002915A CA 3002915 A CA3002915 A CA 3002915A CA 3002915 C CA3002915 C CA 3002915C
Authority
CA
Canada
Prior art keywords
plasminogen
subject
activity
glu
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3002915A
Other languages
English (en)
French (fr)
Other versions
CA3002915A1 (en
Inventor
Martin Robitaille
Karen Thibaudeau
Pierre Laurin
Stacy PLUM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Inc
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of CA3002915A1 publication Critical patent/CA3002915A1/en
Application granted granted Critical
Publication of CA3002915C publication Critical patent/CA3002915C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3002915A 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency Active CA3002915C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
US62/250,235 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (2)

Publication Number Publication Date
CA3002915A1 CA3002915A1 (en) 2017-05-11
CA3002915C true CA3002915C (en) 2024-01-16

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002915A Active CA3002915C (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Country Status (24)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
DK (1) DK3370760T3 (enExample)
ES (1) ES3055824T3 (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
LT (1) LT3370760T (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
PL (1) PL3370760T3 (enExample)
PT (1) PT3370760T (enExample)
RS (1) RS67519B1 (enExample)
RU (1) RU2736831C2 (enExample)
SI (1) SI3370760T1 (enExample)
SM (1) SMT202500451T1 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
US12011455B2 (en) 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
US11129880B2 (en) * 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP3914288A1 (en) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2008026999A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
EP2451835A1 (en) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑

Also Published As

Publication number Publication date
US11291711B2 (en) 2022-04-05
RU2018120182A (ru) 2019-12-04
AU2016347863B2 (en) 2023-11-09
RS67519B1 (sr) 2025-12-31
SMT202500451T1 (it) 2026-01-12
ES3055824T3 (en) 2026-02-16
FI3370760T3 (fi) 2025-12-05
IL258913A (en) 2018-06-28
ZA201802820B (en) 2019-07-31
IL258913B (en) 2021-12-01
CN108289935A (zh) 2018-07-17
JP6878423B2 (ja) 2021-05-26
SI3370760T1 (sl) 2026-02-27
CA3002915A1 (en) 2017-05-11
RU2018120182A3 (enExample) 2020-04-27
BR112018008965A8 (pt) 2019-02-26
KR20180083348A (ko) 2018-07-20
EP3370760A4 (en) 2019-06-26
US20190231854A1 (en) 2019-08-01
LT3370760T (lt) 2025-12-29
AU2016347863A1 (en) 2018-06-07
PL3370760T3 (pl) 2026-03-23
KR102821400B1 (ko) 2025-06-18
WO2017077380A1 (en) 2017-05-11
MX2018005588A (es) 2018-11-09
DK3370760T3 (da) 2025-12-22
NZ742657A (en) 2024-04-26
BR112018008965A2 (pt) 2018-11-21
JP2018533589A (ja) 2018-11-15
TWI801331B (zh) 2023-05-11
PT3370760T (pt) 2025-12-03
EP3370760B1 (en) 2025-10-01
TW201722463A (zh) 2017-07-01
MY199581A (en) 2023-11-07
RU2736831C2 (ru) 2020-11-20
EP3370760A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
US11291711B2 (en) Plasminogen replacement therapy for plasminogen-deficiency
Stefoni et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients
Jude et al. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy
Gando et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients
Ishihara et al. Effect of plasma fibrinogen, high-sensitive C-reactive protein, and cigarette smoking on carotid atherosclerosis: the Suita study
EA002496B1 (ru) Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с
TW201904990A (zh) 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
Roldán et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
Wang et al. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension
AU2018202289A1 (en) Use of serelaxin to reduce GDF-15
Engström et al. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
JP2009520696A (ja) 出血性ショックおよびその続発症を治療するための製剤
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
Pomero et al. Direct oral anticoagulants in factor VII deficiency patient
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Ranieri et al. Defibrotide in the treatment of Raynaud's phenomenon in patients with progressive systemic sclerosis or essential mixed cryoglobulinemia
ADVERSE A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS
Zakaria et al. Plasma lactoferrin level as a predictor to endothelial dysfunction in patients with obstructive sleep apnea
Kageyama et al. Prevention of neointima formation after balloon injury by anti-human vWF monoclonal antibody, AJvW-2 in guinea pigs
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
Lonn et al. Results in Immunology
Martins e Silva The 4th International Symposium on Clinical Haemorheology: Report and Abstracts
Donagaon Factor Viii: C Levels And Macrovascular Complications In Diabetes Mellitus
Mari Gene-environment interactions and vascular risk in the elderly

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210825

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250227

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250329

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022